The cochlea, it turns out, has a robust local immune system of its own. Cochlear resident macrophages are found in several strategic locations, including the spiral ligament, the spiral ganglion — where the cell bodies of auditory neurons live — and in close association with the blood-labyrinth barrier, the specialized vascular gate that shields the inner ear from systemic circulation. These cells express well-known macrophage markers such as IBA1, MHCII, CD163, and CD68, and have been documented in non-diseased human temporal bone samples, underscoring that they carry out normal physiological functions as well as pathological ones. At rest, they adopt a ramified form, extending elaborate branching processes that continuously survey the local microenvironment for debris, damaged cells, and threats to homeostasis. A specialized population known as perivascular-resident macrophage-like melanocytes sits directly within the blood-labyrinth barrier, where they help regulate its permeability.

When injury, noise exposure, or aging strikes, these cells undergo a dramatic transformation. They retract their processes, adopt an ameboid morphology, and acquire phagocytic capacity — the ability to engulf and digest cellular debris. Functionally, they exist along a continuum between two canonical states: M1 classically activated macrophages, which drive pro-inflammatory responses, and M2 alternatively activated macrophages, which promote tissue homeostasis and resolution of inflammation. The morphological landscape is not uniform across the cochlea. In the spiral ganglion, macrophages resemble microglia, the resident immune cells of the brain, extending long processes that contact auditory neurons and surrounding glia. Along the basilar membrane, apical macrophages tend to retain a more quiescent appearance while basal cells adopt an activated phenotype — a pattern that becomes more prominent with age and may reflect the base-to-apex progression of cochlear degeneration characteristic of presbycusis.

The neuroprotective significance of these cells was demonstrated through selective depletion experiments. When researchers administered PLX5622, a CSF-1 receptor inhibitor, to eliminate cochlear macrophages, mice undergoing cochlear implantation showed significantly greater spiral ganglion neuron degeneration compared to animals with intact macrophage populations — and the same acceleration occurred in unoperated control ears. These findings establish that cochlear macrophages are active neuroprotective agents, tempering inflammatory responses and sustaining neuronal integrity under both physiological and stressed conditions. Macrophages also engage directly with Schwann cells, the glial architects of auditory neuron myelination, releasing a context-dependent repertoire of secreted signals — pro-inflammatory mediators such as TNF-α, IL-1β, and IL-6, alongside anti-inflammatory and neurotrophic factors like IL-10 and IGF-1 — that directly influence Schwann cell proliferation and regeneration.

The pathophysiology of age-related hearing loss, the review argues, develops from low-grade chronic inflammation known as inflammaging. In mouse models of presbycusis, activated macrophages were observed in the cochlea prior to detectable hair cell damage and were concentrated near hair cells that subsequently degenerated — suggesting that macrophage activation may drive, rather than simply accompany, sensory cell loss. RNA sequencing of cochlear tissue from mouse models revealed a transcriptionally distinct expansion of pro-inflammatory macrophage populations, and analysis of human temporal bone samples from older donors showed a markedly increased proportion of activated macrophages in the auditory nerve and lateral wall, two structures whose integrity is central to auditory function. In the blood-labyrinth barrier, the number of perivascular-resident macrophage-like melanocytes decreased in aged ears, but a larger proportion of the remaining cells were activated — pointing to both macrophage loss and dysfunction as contributors to age-related pathology.

Several molecular signaling pathways govern this delicate balance. The fractalkine pathway, in which the chemokine CX3CL1 is constitutively expressed on spiral ganglion neurons and hair cells and binds exclusively to the CX3CR1 receptor on immune cells, has emerged as a critical regulator. Disrupting this pathway in knockout mice leads to increased spiral ganglion neuron loss accompanied by elevated IL-1β expression, impaired spontaneous ribbon synapse recovery after noise exposure, and diminished macrophage recruitment after selective hair cell damage. The JAK/STAT pathway, particularly STAT3, promotes M2 polarization in multiple tissues. The PI3K/Akt pathway is involved in both M1 and M2 phenotypes, with downregulation of different AKT isoforms favoring opposite polarization states. The mTOR pathway, inhibited by rapamycin, has been implicated in age-related neuroinflammation, and newer evidence suggests that overactivation secondary to dysregulated upstream activators may lead to sensorineural hearing loss. The MAPK pathway, typically activated downstream of toll-like receptor signaling, is also involved in macrophage activation and polarization.

The broader inflammatory environment in the aging cochlea is further destabilized by a failure of oxidative stress regulation. Mechanisms that clear reactive oxygen species are progressively weakened, lowering the threshold for activation of downstream inflammatory cascades. Chief among these is the NLRP3 inflammasome, a multi-protein complex whose overactivation is implicated in both neurodegenerative disorders and age-related hearing loss. NLRP3 activation follows a two-step process — an initial priming signal followed by activation triggered by pathogen- or damage-associated molecular patterns — leading to caspase-1 activation, release of pro-inflammatory cytokines IL-1β and IL-18, and pyroptotic cell lysis that floods the local microenvironment with inflammatory mediators. Priming can be driven by upstream pathways including TLR9/NF-κB signaling, which elevates expression of IL-6 and TNF-α. Dysregulation of the complement cascade represents an additional amplifying mechanism: complement factor B-deficient mice exhibit progressive hearing loss, spiral ganglion neuron loss, and myelin sheath damage despite structurally intact hair cells — implicating this pathway in glial function and myelination independently of sensory cell pathology.

Therapeutic strategies aimed at rebalancing macrophage polarization are showing promise in preclinical models. Concurrent inhibition of IL-1 and TNF-α using anakinra and etanercept, respectively, protected hearing thresholds in noise-exposed mice. Blockade of IL-6 signaling reduced macrophage activation and improved spiral ganglion neuron survival. Minocycline administration partially preserved hair cells by attenuating macrophage activation following cochlear injury. On the pro-regenerative side, local administration of soluble fractalkine to noise-exposed mice restored synaptic integrity and hearing thresholds — but only in the presence of macrophages. When macrophages were depleted following noise exposure, synaptic and neuronal loss was exacerbated; upon reintroduction, previously depleted mice recovered hearing thresholds, restored ribbon synapses, and preserved spiral ganglion neurons. Mesenchymal stem cells have been shown to suppress pro-inflammatory microglial activation while enhancing neuroprotective states, in part through activation of the fractalkine pathway, and can push macrophage differentiation toward the M2 anti-inflammatory phenotype across multiple organ systems.

Perhaps the most striking finding is that macrophages must be modulated, not eliminated. Complete macrophage depletion appears to worsen outcomes: spiral ganglion neuron degeneration accelerates, synaptic repair fails, and hearing loss deepens. The evidence firmly argues against broad immunosuppressive strategies and in favor of dampening pathological M1 activity while preserving or enhancing M2 neuroprotective and pro-repair functions essential to cochlear homeostasis. Timing of intervention is likely as important as target choice. Macrophage activation and shifts toward pro-inflammatory states have been documented in both animal models and human temporal bone specimens prior to significant hair cell or neuronal loss, suggesting that the immunological changes driving structural degeneration precede — and may be necessary for — that degeneration to occur. Even subclinical hearing loss leaves an immunological footprint: cochlear macrophages exposed to low-level noise leading to temporary threshold shifts exhibited activation and reduced phagocytic capacity, pointing to macrophage priming whereby repeated insults condition the immune system toward exaggerated responses to subsequent stressors.

The broader implications extend beyond hearing. Age-related hearing loss has been independently associated with cognitive decline and increased risk of dementia, though the direction and mechanism of this relationship remain incompletely understood. Given that many of the inflammatory cascades implicated in cochlear macrophage dysregulation are shared with Alzheimer’s disease, Parkinson’s disease, and related disorders — including complement activation, NLRP3 inflammasome signaling, and microglial priming — therapeutic strategies developed for the cochlea may have direct translational relevance to the brain and vice versa. Emerging evidence suggests that cochlear macrophages and central nervous system microglia share transcriptional programs and signaling pathways, offering a valuable first roadmap for inner ear therapeutics derived from neurodegeneration research. The cochlear macrophage, the review concludes, stands at the intersection of protection and pathology in age-related hearing loss — and a more complete understanding of the signals governing this balance offers promise not only for preserving hearing, but for uncovering shared mechanisms of immune-driven neurodegeneration across the nervous system.

Subject of Research: science

Article Title: The cochlear macrophage in presbycusis: inflammaging, neuroinflammation, and targets for therapeutic modulation

Article References: Al-Asad, R. K., & Kempfle, J. S. (2026). The cochlear macrophage in presbycusis: inflammaging, neuroinflammation, and targets for therapeutic modulation. Frontiers in Cellular Neuroscience, 20, Article 1930209. https://doi.org/10.3389/fncel.2026.1930209

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1930209

Keywords: presbycusis, age-related hearing loss, cochlear macrophages, inflammaging, neuroinflammation, fractalkine, NLRP3 inflammasome, complement cascade, microglia, neurodegeneration, cochlear, macrophage